| Timetable |
| Download Conference Program |
| Download All Abstracts |
| Zoom Access |
| Corporate Program |
Poster Presentations
Day 2, June 23（Mon.）
Room P (Maesato East, Foyer, Ocean Wing)
- 2P-AM-03
Overcoming Neoadjuvant Chemotherapy Resistance by Clinical Phosphoproteomics of Colorectal Cancer Liver Metastasis
(1NIBIOHN, 2Kyoto Univ. Gastrointestinal surg., 3Ujitoku, 4JFCR, 5Kyoto Univ. Pharmaceutical Sci.)
oAkina Shinkura1,2, Satoshi Muraoka1, Narimi Takaai1, Yoko Takada1, Masayo Hirano1, Satoshi Nagayama3,4, Yu Takahashi4, Yosuke Fukunaga4, Kazutaka Obama2, Jun Adachi1,5
The curative treatment for colorectal cancer liver metastasis (CRLM) is complete resection by surgery, but due to the high recurrence rate after resection, perioperative chemotherapy including neoadjuvant chemotherapy (NAC) is commonly used for CRLM. However, some patients are resistant to current NAC regimens and its efficacy is still controversial. By using high throughput pre-treatment system, we performed a large-scale clinical phosphoproteome analysis of CRLM samples with (n=37) and without (n=57) NAC in order to explore new treatment strategies to overcome NAC resistance. We quantified 11415 proteins and 57877 phosphorylation sites by LC-MS/MS analysis. We performed Post Translational Modification Signature Enrichment Analysis to investigate kinase activities involved in NAC resistance. Activity of a kinase involved in glucose metabolism and expression of an enzyme involved in glycolysis were elevated in the NAC resistant patients compared to NAC sensitive patients or patients without NAC. We plan to further investigate the impact of this kinase on overcoming NAC resistance in vitro.